Nov 15, 2022 - Nov 17, 2022 / NTS GMT
Tiago Fauth - Credit Suisse Group AG - Analyst
Great. So welcome, everyone, to the 31st Annual Healthcare Conference at Credit Suisse. I am Tiago Fauth; I am a biotech analyst here at Credit Suisse. We're joined today by Spruce Bio. Javier, CEO, is going to do a quick presentation, with some Q&A towards the end.
Javier Szwarcberg - Spruce Biosciences Inc. - CEO
Thank you. Thank you, Tiago. My name is Javier Szwarcberg. It's a real pleasure to be here. I am the CEO of Spruce. I'm going to move forward from our forward-looking statements, which I'll be making along my presentation. And I wanted to first tell you what Spruce is. We are an early-stage biotech company, currently developing tildacerfont for the treatment of CAH as well as PCOS. I'll be spending the majority of my time talking to you about CAH. In the latter part of my deck, I'll discuss some pediatrics -- our pediatric efforts and our PCOS effort.
So CAH is a large, fairly large, market opportunity. It's a $3 billion market opportunity with a high unmet medical need, which was
Spruce Biosciences Inc at Jefferies London Healthcare Conference Transcript
Nov 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers